Small peptide–based agents have attracted wide interest as cancer-targeting agents for diagnostic imaging and targeted therapy. There is a need to develop new high-affinity and high-specificity peptidomimetic or small-molecule ligands against cancer cell surface receptors. Here we report on the identification of a high-affinity peptidomimetic ligand (LLP2A; IC50 = 2 pM) against α4β1 integrin using both diverse and highly focused one-bead-one-compound combinatorial peptidomimetic libraries in conjunction with high-stringency screening. We further demonstrate that LLP2A can be used to image α4β1-expressing lymphomas with high sensitivity and specificity when conjugated to a near infrared fluorescent dye in a mouse xenograft model. Thus, LLP2A provides an important tool for noninvasive monitoring of α4β1 expression and activity during tumor progression, and it shows great potential as an imaging and therapeutic agent for α4β1-positive tumors.
Subscribe to Journal
Get full journal access for 1 year
only $14.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Aina, O.H., Sroka, T.C., Chen, M.L. & Lam, K.S. Therapeutic cancer targeting peptides. Biopolymers 66, 184–199 (2002).
Coiffier, B. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92, 1927–1932 (1998).
Wiseman, G.A. et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99, 4336–4342 (2002).
Okarvi, S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 24, 357–397 (2004).
Holzmann, B., Gosslar, U. & Bittner, M. α4 integrins and tumor metastasis. Curr. Top. Microbiol. Immunol. 231, 125–141 (1998).
Vincent, A.M., Cawley, J.C. & Burthem, J. Integrin function in chronic lymphocytic leukemia. Blood 87, 4780–4788 (1996).
Marco, R.A., Diaz-Montero, C.M., Wygant, J.N., Kleinerman, E.S. & McIntyre, B.W. Alpha 4 integrin increases anoikis of human osteosarcoma cells. J. Cell. Biochem. 88, 1038–1047 (2003).
de la Fuente, M.T., Casanova, B., Garcia-Gila, M., Silva, A. & Garcia-Pardo, A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 13, 266–274 (1999).
Damiano, J.S. & Dalton, W.S. Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma 38, 71–81 (2000).
Matsunaga, T. et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9, 1158–1165 (2003).
Olson, D.L., Burkly, L.C., Leone, D.R., Dolinski, B.M. & Lobb, R.R. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 4, 91–99 (2005).
Garmy-Susini, B. et al. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J. Clin. Invest. 115, 1542–1551 (2005).
Osborn, L. et al. Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (alpha 4 beta 1). J. Cell Biol. 124, 601–608 (1994).
Komoriya, A. et al. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem. 266, 15075–15079 (1991).
Lin, K.C. & Castro, A.C. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr. Opin. Chem. Biol. 2, 453–457 (1998).
Yusuf-Makagiansar, H., Anderson, M.E., Yakovleva, T.V., Murray, J.S. & Siahaan, T.J. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22, 146–167 (2002).
Lowman, H.B. Bacteriophage display and discovery of peptide leads for drug development. Annu. Rev. Biophys. Biomol. Struct. 26, 401–424 (1997).
Weiner, R.E. & Thakur, M.L. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl. Radiat. Isot. 57, 749–763 (2002).
Lam, K.S. et al. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354, 82–84 (1991).
Lam, K.S., Lebl, M. & Krchnak, V. The “one-bead-one-compound” combinatorial library method. Chem. Rev. 97, 411–448 (1997).
Meldal, M., Svendsen, I., Breddam, K. & Auzanneau, F.I. Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity. Proc. Natl. Acad. Sci. USA 91, 3314–3318 (1994).
Spring, D.R., Krishnan, S., Blackwell, H.E. & Schreiber, S.L. Diversity-oriented synthesis of biaryl-containing medium rings using a one bead/one stock solution platform. J. Am. Chem. Soc. 124, 1354–1363 (2002).
Copeland, G.T. & Miller, S.J. Selection of enantioselective acyl transfer catalysts from a pooled peptide library through a fluorescence-based activity assay: an approach to kinetic resolution of secondary alcohols of broad structural scope. J. Am. Chem. Soc. 123, 6496–6502 (2001).
Liu, R., Marik, J. & Lam, K.S. A novel peptide-based encoding system for “one-bead one-compound” peptidomimetic and small molecule combinatorial libraries. J. Am. Chem. Soc. 124, 7678–7680 (2002).
Song, A.M., Zhang, J.H., Lebrilla, C.B. & Lam, K.S. A novel and rapid encoding method based on mass spectrometry for “One-Bead One-Compound” small molecule combinatorial libraries. J. Am. Chem. Soc. 125, 6180–6188 (2003).
Affleck, R.L. Solutions for library encoding to create collections of discrete compounds. Curr. Opin. Chem. Biol. 5, 257–263 (2001).
Park, S.I. et al. The use of one-bead one-compound combinatorial library method to identify peptide ligands for alpha-4-beta-1 integrin receptor in non-Hodgkin's lymphoma. Lett. Pept. Sci. 8, 171–178 (2002).
Lin, K. et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J. Med. Chem. 42, 920–934 (1999).
Falcioni, R. et al. Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Exp. Cell Res. 210, 113–122 (1994).
Irie, A., Kamata, T., Puzon-McLaughlin, W. & Takada, Y. Critical amino acid residues for ligand binding are clustered in a predicted beta-turn of the third N-terminal repeat in the integrin alpha 4 and alpha 5 subunits. EMBO J. 14, 5550–5556 (1995).
Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med. 9, 123–128 (2003).
Becker, A. et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. 19, 327–331 (2001).
Wilbur, D.S., Hamlin, D.K., Sanderson, J. & Lin, Y. Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization. Bioconjug. Chem. 15, 1454–1463 (2004).
Singh, J. et al. Identification of potent and novel alpha4beta1 antagonists using in silico screening. J. Med. Chem. 45, 2988–2993 (2002).
Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 (2002).
Shimaoka, M., Takagi, J. & Springer, T.A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31, 485–516 (2002).
Rivera-Nieves, J. et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J. Immunol. 174, 2343–2352 (2005).
Chen, X. et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol. Imaging 3, 96–104 (2004).
Venditto, V.J., Regino, C.A. & Brechbiel, M.W. PAMAM dendrimer based macromolecules as improved contrast agents. Mol. Pharm. 2, 302–311 (2005).
McIntyre, J.O. et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem. J. 377, 617–628 (2004).
Boerman, O.C., van Schaijk, F.G., Oyen, W.J. & Corstens, F.H. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 44, 400–411 (2003).
Rosebrough, S.F. Two-step immunological approaches for imaging and therapy. Q. J. Nucl. Med. 40, 234–251 (1996).
Yang, J.T., Rayburn, H. & Hynes, R.O. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 121, 549–560 (1995).
Spies, S.M. Imaging and dosing in radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). Semin. Nucl. Med. 34, 10–13 (2004).
Fields, G.B. & Noble, R.L. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161–214 (1990).
Kaiser, E., Colescott, R.L., Bossinger, C.D. & Cook, P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34, 595–598 (1970).
Kamata, T., Puzon, W. & Takada, Y. Identification of putative ligand binding sites within I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29). J. Biol. Chem. 269, 9659–9663 (1994).
Kamata, T., Wright, R. & Takada, Y. Critical threonine and aspartic acid residues within the I domains of beta 2 integrins for interactions with intercellular adhesion molecule 1 (ICAM-1) and C3bi. J. Biol. Chem. 270, 12531–12535 (1995).
Eto, K. et al. Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. J. Biol. Chem. 277, 17804–17810 (2002).
Tarui, T., Miles, L.A. & Takada, Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J. Biol. Chem. 276, 39562–39568 (2001).
This work was supported by the National Institutes of Health (R33CA-86364, R33CA-99136 and U19CA113298) and the National Science Foundation (CHE-0302122). The 500-MHz NMR spectrometer was purchased in part with the grant NSF 9724412. We thank R. Wisdom, A. Lehman, S.M. Dixon and A. Enstrom for editorial assistance.
The authors declare no competing financial interests.
Characterization of LLP2A (PDF 94 kb)
The 30 isocyanates in the X1 position of the initial library (PDF 23 kb)
The 14 nitro-containing compounds in the X2 position of the initial library (PDF 21 kb)
The 20 Lys derivatives derived from carboxylic acids in the X3 position of the initial library (PDF 25 kb)
Building blocks at positions X3, X4, and X5 of the initial library (PDF 34 kb)
The 45 amino acids at positions X6, X7, and X8 of the initial library (PDF 25 kb)
Building blocks at positions of X3, X4, and X5 of the focused library (PDF 46 kb)
About this article
Cite this article
Peng, L., Liu, R., Marik, J. et al. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat Chem Biol 2, 381–389 (2006). https://doi.org/10.1038/nchembio798
Surface modification of polymeric electrospun scaffolds via a potent and high-affinity integrin α4β1 ligand improved the adhesion, spreading and survival of human chorionic villus-derived mesenchymal stem cells: a new insight for fetal tissue engineering
Journal of Materials Chemistry B (2020)
Incorporation of Fluorine into an OBOC Peptide Library by Copper-Free Click Chemistry toward the Discovery of PET Imaging Agents
ACS Combinatorial Science (2020)
Developing an Injectable Nanofibrous Extracellular Matrix Hydrogel With an Integrin αvβ3 Ligand to Improve Endothelial Cell Survival, Engraftment and Vascularization
Frontiers in Bioengineering and Biotechnology (2020)
Amino Acids (2020)
Nature Communications (2020)